Skip to main navigation

Investor Relations

Overview
News & Events
Press Releases Events & Presentations
Financial Info
SEC Filings Annual Reports Quarterly Results
Stock
Stock Quote & Chart Historic Price Lookup
Governance
Documents & Charters Leadership Board of Directors Advisors Committee Composition
Shareholder Resources
FAQs Email Alerts Contact IR RSS Feeds

Press Releases

Year

Reviva Pharmaceuticals Receives FDA Orphan Designation for RP5063 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Apr 09, 2018

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 11 - 11 of 11

Shareholder Tools

Print Page
Email Alerts
RSS
FAQs

© Reviva Pharmaceuticals © 2021. All Rights Reserved.